{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:22:49Z","timestamp":1766514169264,"version":"build-2065373602"},"reference-count":44,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,5,1]],"date-time":"2020-05-01T00:00:00Z","timestamp":1588291200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001322","name":"South African Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001322","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001342","name":"Department of Science and Technology, Republic of South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001342","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2020,5]]},"DOI":"10.1016\/j.vaccine.2020.03.045","type":"journal-article","created":{"date-parts":[[2020,4,16]],"date-time":"2020-04-16T07:28:34Z","timestamp":1587022114000},"page":"3862-3868","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children"],"prefix":"10.1016","volume":"38","author":[{"given":"Eleonora A.M.L.","family":"Mutsaerts","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta C.","family":"Nunes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sutika","family":"Bhikha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benit T.","family":"Ikulinda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Jose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthonet","family":"Koen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Moultrie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diederick E.","family":"Grobbee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kerstin","family":"Klipstein-Grobusch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adriana","family":"Weinberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shabir A.","family":"Madhi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2020.03.045_b0005","doi-asserted-by":"crossref","first-page":"20405","DOI":"10.7189\/jogh.06.020405","article-title":"Population-level effectiveness of PMTCT option A on early mother-to-child (MTCT) transmission of HIV in South Africa: implications for eliminating MTCT","volume":"6","author":"Goga","year":"2016","journal-title":"J Glob Health"},{"key":"10.1016\/j.vaccine.2020.03.045_b0010","doi-asserted-by":"crossref","first-page":"e92","DOI":"10.1016\/S1473-3099(16)00055-4","article-title":"HIV-exposed, uninfected infants: new global challenges in the era of paediatric HIV elimination","volume":"16","author":"Evans","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.045_b0015","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/tropej\/fms019","article-title":"HIV-exposed uninfected infants are at increased risk for severe infections in the first year of life","volume":"58","author":"Slogrove","year":"2012","journal-title":"J Trop Pediatr"},{"key":"10.1016\/j.vaccine.2020.03.045_b0020","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1016\/j.vaccine.2010.08.037","article-title":"Hepatitis A virus seroprevalence by age and world region, 1990 and 2005","volume":"28","author":"Jacobsen","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.045_b0025","unstructured":"Institute for Health Metrics and Evaluation. GDB results tool - Global Health Data Exchange. Glob Burd Dis Study 2017 2017. http:\/\/ghdx.healthdata.org\/gbd-results-tool (accessed September 26, 2019)."},{"key":"10.1016\/j.vaccine.2020.03.045_b0030","first-page":"261","article-title":"WHO position paper on hepatitis A vaccines \u2013 June 2012","volume":"87","author":"World Health Organization","year":"2012","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2020.03.045_b0035","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s13643-015-0112-5","article-title":"Epidemiology of hepatitis A virus in Africa among persons aged 1\u201310 years: a systematic review protocol","volume":"4","author":"Kanyenda","year":"2015","journal-title":"Syst Rev"},{"key":"10.1016\/j.vaccine.2020.03.045_b0040","first-page":"20","article-title":"Seroprevalence and predictors of hepatitis A infection in Nigerian children","volume":"120","author":"Ikobah","year":"2015","journal-title":"Pan Afr Med J"},{"key":"10.1016\/j.vaccine.2020.03.045_b0045","doi-asserted-by":"crossref","first-page":"279","DOI":"10.4103\/0300-1652.137185","article-title":"Hepatitis A virus in West Africa: Is an epidemiological transition beginning?","volume":"55","author":"Jacobsen","year":"2014","journal-title":"Niger Med J"},{"key":"10.1016\/j.vaccine.2020.03.045_b0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0216033","article-title":"Hepatitis A virus seroprevalence in South Africa - Estimates using routine laboratory data, 2005\u20132015","volume":"14","author":"Haeri Mazanderani","year":"2019","journal-title":"PLoS ONE"},{"key":"10.1016\/j.vaccine.2020.03.045_b0055","doi-asserted-by":"crossref","DOI":"10.2147\/HMER.S33847","article-title":"Persistence of immunity from 1 year of age after one or two doses of hepatitis A vaccine given to children in Argentina","author":"Espul","year":"2012","journal-title":"Hepatic Med Evid Res"},{"key":"10.1016\/j.vaccine.2020.03.045_b0060","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1080\/21645515.2017.1358326","article-title":"Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina","volume":"13","author":"Espul","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2020.03.045_b0065","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1086\/432055","article-title":"Immunogenicity and Tolerability of Hepatitis A Vaccine in HIV-Infected Children","volume":"41","author":"Gouvea","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.045_b0070","article-title":"Working group on varicella and herpes zoster vaccines. background paper on varicella","author":"World Health Organization. SAGE","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.045_b0075","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/S0140-6736(06)69561-5","volume":"368","author":"Heininger","year":"2006","journal-title":"Varicella. Lancet"},{"key":"10.1016\/j.vaccine.2020.03.045_b0080","first-page":"265","article-title":"Varicella and herpes zoster vaccines: WHO position paper","volume":"25","author":"World Health Organization","year":"2014","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2020.03.045_b0085","unstructured":"Gabutti G, Franchi M, Maniscalco L, Stefanati A. Varicella-zoster virus: pathogenesis, incidence patterns and vaccination programs. Minerva Pediatr 2016;68:213\u201325. https:\/\/doi.org\/R15Y2016N03A0213 [pii]."},{"key":"10.1016\/j.vaccine.2020.03.045_b0090","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1080\/21645515.2018.1559687","article-title":"Varicella healthcare resource utilization in middle income countries: a pooled analysis of the multi-country MARVEL study in Latin America & Europe","volume":"15","author":"Wolfson","year":"2019","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.03.045_b0095","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1093\/infdis\/jiz348","article-title":"Immunogenicity and safety of an early measles vaccination schedule at 6 and 12 months of age in human immunodeficiency virus (HIV)-unexposed and HIV-exposed, uninfected south African children","volume":"220","author":"Mutsaerts","year":"2019","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.045_b0100","unstructured":"Abbott. ARCHITECT HAVAb-IgG package insert. 6C29, B6C290, 36-6800\/R1 2004:1\u20136. http:\/\/www.ilexmedical.com\/files\/PDF\/HAVAb-IgG_AEC.pdf (accessed November 7, 2019)."},{"key":"10.1016\/j.vaccine.2020.03.045_b0105","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1128\/JCM.00719-06","article-title":"Serological detection of varicella-zoster virus-specific immunoglobulin G by an enzyme-linked immunosorbent assay using glycoprotein antigen","volume":"44","author":"Sauerbrei","year":"2006","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.vaccine.2020.03.045_b0110","doi-asserted-by":"crossref","unstructured":"Gershon AA, Marin M, Seward JF. Varicella Vaccines. In: Plotkin SA, Orenstein WA, Offit PA, Edwards KM, editors. Plotkin\u2019s Vaccines. 7th ed., Elsevier; 2018, p. 1145\u201380. https:\/\/doi.org\/10.1016\/C2013-0-18914-3.","DOI":"10.1016\/B978-0-323-35761-6.00062-6"},{"key":"10.1016\/j.vaccine.2020.03.045_b0115","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1080\/21645515.2016.1278329","article-title":"Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine","volume":"13","author":"Zhang","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2020.03.045_b0120","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1093\/infdis\/jiw411","article-title":"Single-dose hepatitis a immunization: 7.5-year observational pilot study in nicaraguan children to assess protective effectiveness and Humoral immune memory response","volume":"214","author":"Mayorga","year":"2016","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.045_b0125","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1016\/j.vaccine.2015.06.099","article-title":"A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection","volume":"33","author":"Melga\u00e7o","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.045_b0130","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1093\/cid\/civ734","article-title":"Prevalence and persistence of varicella antibodies in previously immunized children and youth with perinatal HIV-1 infection","volume":"62","author":"Purswani","year":"2016","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.045_b0135","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/01.inf.0000109287.97518.67","article-title":"Ten year follow-up of healthy children who received one or two injections of varicella vaccine","volume":"23","author":"Kuter","year":"2004","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.03.045_b0140","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1097\/01.inf.0000172901.29621.e9","article-title":"Dose-response study of a quadrivalent measles, mumps, rubella and varicella vaccine in healthy children","volume":"24","author":"Shinefield","year":"2005","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.03.045_b0145","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/01.inf.0000207857.10947.1f","article-title":"Safety and immunogenicity of a measles, mumps, rubella and varicella vaccine given with combined Haemophilus influenzae type b conjugate\/hepatitis B vaccines and combined diphtheria-tetanus-acellular pertussis vaccines","volume":"25","author":"Shinefield","year":"2006","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.03.045_b0150","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1097\/INF.0b013e318292f7b1","article-title":"Antibody persistence and booster vaccination of a fully liquid hexavalent vaccine coadministered with measles\/mumps\/rubella and varicella vaccines at 15\u201318 months of age in healthy South African infants","volume":"32","author":"Madhi","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2020.03.045_b0155","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1093\/infdis\/174.Supplement_3.S324","article-title":"Immunogenicity and Safety of a live attenuated varicella vaccine (Oka\/SB Bio) in healthy children","volume":"174","author":"Meurice","year":"1996","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.045_b0160","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1086\/529043","article-title":"Primary vaccine failure after 1 dose of varicella vaccine in healthy children","volume":"197","author":"Michalik","year":"2008","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.045_b0165","unstructured":"GlaxoSmithKline. Varilrix\u00ae Product Information. Varicella Vaccine, live attenuated 2017:1\u201314. au.gsk.com\/media\/365011\/varilrix_pi_009_01_%0Aapproved.pdf (accessed October 9, 2019)."},{"key":"10.1016\/j.vaccine.2020.03.045_b0170","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.4161\/hv.24035","article-title":"Immunogenicity and safety of combined measles-mumps-rubella-varicella vaccine using new measles and rubella working seeds in healthy children in Taiwan and Singapore","volume":"9","author":"Huang","year":"2013","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.03.045_b0175","doi-asserted-by":"crossref","first-page":"4278","DOI":"10.1016\/j.vaccine.2016.07.009","article-title":"The immunogenicity and safety of a tetravalent measles-mumps- rubella-varicella vaccine when co-administered with conjugated meningococcal C vaccine to healthy children : A phase IIIb, randomized, multi-center study in Italy","volume":"34","author":"Durando","year":"2016","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2020.03.045_b0180","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1080\/21645515.2014.1004031","article-title":"Safety and immunogenicity of single dose live attenuated varicella vaccine (VR 795 Oka strain) in healthy Indian children: A randomized controlled study","volume":"11","author":"Mitra","year":"2015","journal-title":"Hum Vaccin Immunother"},{"key":"10.1016\/j.vaccine.2020.03.045_b0185","unstructured":"CDC - Centers for Disease Control and Prevention. Chickenpox (Varicella). Interpreting laboratory tests 2018. cdc.gov\/%0Achickenpox\/hcp\/lab-tests.html (accessed October 9, 2019)."},{"key":"10.1016\/j.vaccine.2020.03.045_b0190","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12879-017-2815-9","article-title":"Varicella zoster virus-associated morbidity and mortality in Africa \u2013 A systematic review","volume":"17","author":"Hussey","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.vaccine.2020.03.045_b0195","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1080\/21645515.2016.1242539","article-title":"Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines\u2013A systematic review","volume":"13","author":"Stuurman","year":"2017","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.vaccine.2020.03.045_b0200","unstructured":"Jeena PM, Wesley AG, Coovadia HM. Infectious diseases at the paediatric isolation units of Clairwood and King Edward VIII Hospitals, Durban. Trends in admission and mortality rates (1985-1996) and the early impact of HIV (1994-1996). South African Med J 1998;88:867\u201372."},{"key":"10.1016\/j.vaccine.2020.03.045_b0205","first-page":"1","article-title":"The potential impact of Varicella vaccination in low to middle income countries: a feasibility modeling study","author":"Brisson","year":"2014","journal-title":"Rep to SAGE Work Gr Varicella Herpes Zoster Vaccines"},{"key":"10.1016\/j.vaccine.2020.03.045_b0210","doi-asserted-by":"crossref","first-page":"e1134","DOI":"10.1542\/peds.2013-0863","article-title":"Impact of a routine two-dose varicella vaccination program on varicella epidemiology","volume":"132","author":"Bialek","year":"2013","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2020.03.045_b0215","doi-asserted-by":"crossref","first-page":"593","DOI":"10.2471\/BLT.13.132142","article-title":"Varicella and herpes zoster hospitalizations before and after implementation of one-dose varicella vaccination in Australia: an ecological study","volume":"92","author":"Heywood","year":"2014","journal-title":"Bull World Health Organ"},{"key":"10.1016\/j.vaccine.2020.03.045_b0220","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1080\/21645515.2018.1546525","article-title":"Global impact of varicella vaccination programs","volume":"15","author":"Varela","year":"2019","journal-title":"Hum Vaccin Immunother"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20304333?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X20304333?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:43:10Z","timestamp":1759401790000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X20304333"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5]]},"references-count":44,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2020,5]]}},"alternative-id":["S0264410X20304333"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.045","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2020,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term immunogenicity and safety of hepatitis-A and varicella vaccines in HIV-exposed uninfected and HIV-unexposed South African children","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2020.03.045","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}